New Delhi, July 23 -- Dr Reddy's Laboratories Ltd's US generics business slumped in the June quarter as it faced price erosion in key products like gRevlimid used to treat cancer.

US generics revenue declined 11% year-on-year and 4% sequentially to Rs.3,412 crore in the first quarter of FY26, according to earnings announced on Wednesday. The business accounts for 40%, the highest among all segments, of its top line.

The base business remains stable despite the price erosion, the company's management said in a post-earnings press conference.

"This time, as we knew, we are in the last year of lenalidomide or Revlimid [exclusivity], so this actually was very predictable," said chief executive officer Erez Israeli. He added that the timing...